PhD
Assistant Professor, Genetics
Computational Medicine Program
UNC-Chapel Hill
Breast Cancer
Area of Interest
Our lab investigates the mechanisms underlying fractional resistance to cancer therapies, with a particular focus on cell cycle plasticity in ER+/HER2− breast cancer. Despite significant clinical advancements using CDK4/6 inhibitors such as palbociclib, a small fraction of tumor cells continue to proliferate, posing significant challenges to treatment efficacy. Our research employs cutting-edge multiplex single-cell proteomics, particularly iterative indirect immunofluorescent imaging (4i), combined with advanced computational analyses, to dissect the heterogeneity in cell cycle regulation among individual tumor cells. By mapping the trajectories of resistant cells, we aim to identify molecular signatures associated with resistance, including alterations in key regulators such as E2F1, CDK2, and retinoblastoma protein (RB). Our ultimate goal is to leverage this understanding of cellular plasticity to uncover vulnerabilities within resistant cell populations. Current and future directions of our research also include applying this innovative approach to investigate drug resistance in other cancer types. Through integrative approaches combining 4i proteomics, single-cell analysis, and targeted pharmacological interventions, we seek to inform the development of more effective therapeutic strategies and predictive biomarkers to enhance patient outcomes across multiple malignancies.
Awards and Honors
- UNC Computational Medicine Program Pilot Award, UNC-Chapel Hill, 2023
